Genpact's 24% Growth Engine Is Raising the Stakes Around This AI Turnaround

Genpact's Q2 beat mattered because the mix shifted

Genpact did more than post a clean quarter. It showed that growth was being driven by a higher-value part of the business. Adjusted EPS came in at $1.00 on $1.34 billion of revenue, beating Wall Street's $0.96 and $1.33 billion expectations. The immediate question is no longer whether Genpact can execute; it is whether the company is becoming structurally richer.

Advanced Technology Solutions is doing the heavy lifting

Advanced Technology Solutions grew 24.1% and now represent 27% of total net revenue. That matters because ATS includes Genpact's AI, data, digital, advisory, and agentic offerings, which sit above the older, slower core services base. Core Business Services still accounted for most sales at $980 million, but its growth was only 1.9%. The story this quarter was the mix shift.

Management also raised the bar on expectations, saying it now expects Advanced Technology Solutions revenue to grow at least 25% for the full year and that it is on track to book more than $1 billion in agentic contract value in 2026. One strong quarter does not settle the debate, but it does make the transformation harder to dismiss as just an AI narrative.

What changed inside the business

Genpact posted 7.1% revenue growth while its legacy base kept growing slowly. Core Business Services grew 1.9%, after 1.4% year over year growth in the prior quarter. That slowdown matters because core services is still the larger part of the business. Still, Genpact did not need the legacy base to surge for Q2 to work. Advanced Technology Solutions was strong enough to pull total growth ahead.

Margin expansion suggests the model is improving

This is the part that makes the quarter more meaningful than a simple top-line beat. Genpact said its mix is shifting toward fixed-fee, consumption-based, and outcome-based contracts, while non-FTE revenue moved above half of total revenue. That does not prove every new contract is highly profitable, but it does suggest Genpact is moving away from pure staffing intensity and gaining more control over how work gets delivered.

The financials support that read. Gross margin reached 36.5%, and the company logged its 13th consecutive quarter of gross-margin expansion. For a service business, that is a useful signal that a faster-growing, higher-value mix can lift results even while the older business stays sluggish.

Bookings and backlog make the quarter harder to ignore

A single quarter can always be treated as a snapshot. The pipeline commentary makes the case stronger. Management cited record bookings and an increasing backlog. In the first quarter, leadership had already pointed to unusually strong awarded work, and agentic bookings nearly doubled total contract value in the quarter versus the full prior year. Added to management's update that it is on track for more than $1 billion in agentic contract value in 2026, the message is that client interest is translating into contracts.

What investors should watch next

The next few quarters are the real test. Investors now need proof that the fast-growing ATS segment is lifting the broader business rather than simply offsetting slower growth in core services. The clearest scoreboard will be whether Genpact can sustain growth, protect margins, and keep improving the commercial mix as it moves through the current pipeline.

What would confirm the rerating

• ATS growth stays elevated and continues to lift overall revenue quality.
• Margin expansion holds as the mix shifts toward higher-value work.
• The share of non-FTE, fixed-fee, consumption-based, and outcome-based contracts keeps rising.
• Strong bookings and backlog convert into sustained revenue and earnings momentum.

What would break the story

• Core services weakness starts to overwhelm ATS growth instead of being offset by it.
• The commercial mix drifts backward toward more staffing-heavy work.
• Margin gains stall even if headline growth remains decent.
• Bookings momentum fades before it becomes recurring revenue.

The key question now is simple: can Genpact turn one strong quarter into several quarters of better mix, better margins, and better quality of growth?